EN | TR
E-ISSN: 2602-2974
Macrophage Activation Syndrome in COVID-19 Intensive Care: A Case Report
PDF
Cite
Share
Request
Case Report
VOLUME: 18 ISSUE: 1
P: 57-60
March 2020

Macrophage Activation Syndrome in COVID-19 Intensive Care: A Case Report

J Turk Soc Intens Care 2020;18(1):57-60
DOI: 10.4274/tybd.galenos.2020.80299
Tümay Çakır 1
Canan Gürsoy 1
Nuray Topçuoğlu 2
1. Muğla Sıtkı Koçman Üniversitesi Eğitim ve Araştırma Hastanesi, Anestezi ve Reanimasyon Kliniği, Muğla, Türkiye
2. Muğla Sıtkı Koçman Üniversitesi Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları Kliniği, Muğla, Türkiye
3. Muğla Sıtkı Koçman Üniversitesi Eğitim ve Araştırma Hastanesi, Anestezi ve Reanimasyon Kliniği, Muğla, Türkiye
No information available.
No information available
Received Date: 07.07.2020
Accepted Date: 05.08.2020
Publish Date: 14.10.2020
PDF
Cite
Share
Request

ABSTRACT

Macrophage activation syndrome is a life-threatening condition resulting from the destruction of organs and tissues secondary to excessive activation of the immune system. The cytokine storm that develops during a corona virus infection has some overlapping laboratory and clinical findings to the hemophagocytic syndrome. It is curcial to support the diagnosis and differential diagnosis of this disease with successive measurements of the inflammation markers so as to initiate the treatment process immediately. We have reported here the case of a 44-yearold patient who was treated with tocilizumab for hemophagocytic syndrome that developed during his corona virus infection. The patient was sucessfully treated and monitored as per the pandemic requirement and then discharged. He showed no sequela and has completely recovered.

Keywords: Macrophage activation syndrome, inflammation markers, tocilizumab

References

1
Pachlopnik Schmid J, Côte M, Ménager MM, Burgess A, Nehme N, Ménasché G, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev 2010;235:10-23.
2
Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999;286:1957-9.
3
Filipovich A, McClain K, Grom A. Histiocytic disorders: recentin sights into pathophysiology and practical guidelines.  Biol Blood Marrow Transplant 2010;16(Suppl 1):S82-9.
4
Bergsten E, Horne A, Aricó M, Astigarraga I, Maarten Egeler R, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 2017;130:2728-38.
5
Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis 2003;36:306-12.
6
Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood 2011;118:4041-52.
7
Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford) 2008;47:1686-91.
8
Jovanovic A, Kuzmanovic M, Kravljanac R, Micic D, Jovic M, Gazikalovic S, et al. Central nervous system involvement in hemophagocytic lymphohistiocytosis: a single-center experience. Pediatr Neurol 2014;50:233-7.
2024 ©️ Galenos Publishing House